Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
AADvac1 Axon peptide 108 conjugated to KLH Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) Axon Neuroscience SE Tau Immunotherapy (active)
Bepranemab UCB0107 ,
UCB 0107 ,
Antibody D
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Hoffmann-La Roche, UCB S.A. Tau Immunotherapy (passive)
LY3372689 Alzheimer's Disease (Phase 2) Eli Lilly & Co. Tau Small Molecule
Semorinemab RO7105705 ,
MTAU9937A,
RG6100
Alzheimer's Disease (Phase 2) AC Immune SA, Genentech, Hoffmann-La Roche Tau Immunotherapy (passive)